Literature DB >> 15678272

Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation.

A Girolami1, M Morello, B Girolami, A M Lombardi, C Bertolo.   

Abstract

Twenty-one patients (12 female and 9 male) with severe (homozygous) factor XII (FXII) deficiency and 58 (32 female and 26 male) with heterozygous FXII deficiency were observed for an average 16.2 years. No patient with homozygous FXII deficiency experienced myocardial infarction or any other arterial thrombosis. The same was true for heterozygotes. The cases of FXII deficiency and arterial thrombosis reported in the literature were evaluated. In every instance, associated risk factors were present that could justify the arterial thrombosis. Dyslipidemia, hypertension, smoking, and diabetes mellitus were the most frequent findings. The examination of the few papers that dealt with the prevalence of arterial thrombosis in patients with severe FXII deficiency showed that only 1 patient of 61 experienced myocardial infarction. In conclusion, it seems that the role of FXII deficiency in the pathogenesis of arterial thrombosis is minor.

Entities:  

Mesh:

Year:  2005        PMID: 15678272     DOI: 10.1177/107602960501100105

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  10 in total

1.  Relationship between factor XII deficiency and thrombosis: the debate is still open?

Authors:  Gianfranco Lessiani; Angela Falco; Elvira Nicolucci; Giancarlo Rolandi; Giovanni Davì
Journal:  J Thromb Thrombolysis       Date:  2009-04-08       Impact factor: 2.300

Review 2.  Pregnancies and oral contraceptive therapy in severe (homozygons) FXII deficiency: a study in 12 patients and review of the literature.

Authors:  A Girolami; N Zocca; B Girolami; A M Lombardi; F Fabris
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

Review 3.  Factor XI and XII as antithrombotic targets.

Authors:  Felicitas Müller; David Gailani; Thomas Renné
Journal:  Curr Opin Hematol       Date:  2011-09       Impact factor: 3.284

4.  Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.

Authors:  A Girolami; N Candeo; G Berti De Marinis; E Bonamigo; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

5.  Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period.

Authors:  Antonio Girolami; Silvia Ferrari; Elisabetta Cosi; Bruno Girolami; Maria Luigia Randi
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 6.  The procoagulant and proinflammatory plasma contact system.

Authors:  Thomas Renné
Journal:  Semin Immunopathol       Date:  2011-08-20       Impact factor: 9.623

Review 7.  The many faces of the contact pathway and their role in thrombosis.

Authors:  Rebecca S Woodruff; Bruce Sullenger; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

8.  Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis.

Authors:  Gianfranco Lessiani; Angela Falco; Elvira Nicolucci; Giancarlo Rolandi; Giovanni Davì
Journal:  J Thromb Thrombolysis       Date:  2008-04-06       Impact factor: 2.300

9.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

10.  Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis.

Authors:  Christoph Kleinschnitz; Guido Stoll; Martin Bendszus; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; Christoph Renné; David Gailani; Bernhard Nieswandt; Thomas Renné
Journal:  J Exp Med       Date:  2006-03-13       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.